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Abstract 
Male gender and family history are risk factor for abdominal aortic aneurysm (AAA). We 
hypothesised that genes involved in sex hormones might be important in AAA. We investigated the 
association of aortic diameter with single nucleotide polymorphisms (SNPs) in genes determining 
circulating sex hormones and their action. We genotyped 74 tagging SNPs across 4 genes (steroid 
5α reductase, subfamily A, polypeptide 1 (SRD5A1), cytochrome P450, family 19, subfamily A, 
polypeptide 1 (CYP19A1), androgen receptor (AR) and estrogen receptor 2 (ESR2)) related to sex 
hormone production and action in 1711 men, 640 of whom had an AAA. One genotype was also 
assessed in an independent cohort of 782 men, of whom 513 had large AAAs. Associations were 
assessed adjusting for other risk factors for AAA. One SNP in CYP19A1 was strongly associated 
with aortic diameter. Subjects who had the rare homozygote genotype (TT) for CYP19A1 
g.49412370C>T (SNP ID rs1961177), had increased aortic diameter (coefficient 5.058, standard 
error 1.394, p=0.0003, under a recessive model). This SNP was not associated with aortic diameter 
in an independent cohort which included patients with larger AAAs. Our findings do not support an 
important role of genetic polymorphisms in genes determining sex hormones in aortic dilatation in 
men. The association of one SNP in CYPA9A1 with small but not large AAA may suggest 
differences between AAA formation and progression. This SNP warrants further investigation in 
another large population including patients with small AAAs. 
Key words: Aorta; aneurysm; sex hormones. 
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 Introduction 
Abdominal aortic aneurysm (AAA) primarily affects men with population screening studies 
demonstrating an increased prevalence of approximately 5-fold compared to women1. Currently the 
reasons for the male propensity for AAA are not known but maybe linked to sex hormones, since in 
experimental models androgens have been positively linked to aortic dilatation2. The production, 
metabolism and response to sex hormones is controlled by an array of enzymes and receptors, 
including steroid 5α reductase, aromatase (estrogen synthetase),  androgen and estrogen receptors3,4. 
Steroid 5α reductase enzymes are responsible for the conversion of testosterone to the more potent 
androgen dihydrotestosterone3. Aromatase (estrogen synthetase) is a cytochrome P450 enzyme that 
converts androgen precursor steroids to estrogens4. The responses to circulating sex hormones are 
determined by the androgen and estrogen receptors. Genetic factors appear to play an important role 
in the production, metabolism and response to male sex hormones and therefore maybe relevance to 
AAA, which has been shown to have inherited risk factors5,6. We selected 4 genes important in the 
production, metabolism and response to sex hormones in which to examine the association of 
genetic polymorphisms with aortic dilatation. We hypothesised that single nucleotide 
polymorphisms (SNPs) in the steroid 5α reductase, subfamily A, polypeptide 1 (SRD5A1), 
cytochrome P450, family 19, subfamily A, polypeptide 1 (CYP19A1), androgen receptor (AR) and 
estrogen receptor 2 (ESR2) genes were associated with aortic dilatation and examined this within 
sub-set of the Health In Men Study (HIMS). We attempted to replicate any positive associations in 
an independent cohort from New Zealand. 
 
Methods 
Study design and subjects: HIMS consists of a cohort of men who originally participated in a trial 
of screening for AAA and has been previously described in detail7,8. For the current study 
genotyping was undertaken in all men with AAAs from whom DNA was available (n=640) and 
1071 randomly selected age-matched men without an AAA as controls. Any SNPs found to be 
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significantly associated with aortic diameter were further assessed in an independent cohort of 
subjects from New Zealand9. These subjects included 513 men with large AAAs (80% had 
undergone aortic repair) and 269 healthy elderly men from the same region of Otago. All subjects 
included in both cohorts had undergone abdominal ultrasound. Ultrasound reproducibility was 
assessed during subject recruitment and 95% confidence intervals were <3mm9. The definitions of 
clinical risk factors such as hypertension, dyslipidemia, diabetes, coronary heart disease (CHD) and 
waist to hip ratio were as previously described7.  
Genotyping: The Haploview software package was used to define the linkage disequilibrium blocks 
and to choose tagging SNPs within the location of SRD5A1 (n=14), CYP19A1 (n=39), AR (n=5) and 
ESR2 (n=16) genes using HapMap Phase II data utilising a pairwise approach (minor allele 
frequency >5% and r2 >0.8)10. Regions analysed included the entire gene, plus additional sequences 
10 kb upstream and downstream of the gene. With this approach 100% of the variation in the genes 
was captured. Genotyping on the HIMS subjects was carried out using the Illumina Golden Gate® 
assay on an Illumina BeadLab System at University of Western Australia. Genotype calls were 
made using Bead Studio Genotyping Module software package Version 3.1 (Illumina, Inc., San 
Diego, CA). Mono-allelic SNPs and those with genotyping efficiency <15% were excluded. As a 
result findings for SRD5A1 g.10386C>G (SNP ID rs4702379), SRD5A1 g.720102C>T (SNP ID 
rs6872996), CYP19A1 g.1667A>C (SNP ID rs2445768), CYP19A1 g.16698C>T (SNP ID 
rs8025374), AR g.98970A>G (SNP ID rs2361634) and ESR2 g.63762130G>T (SNP ID 
rs1152583) were excluded. Genotyping efficiency for the other 68 SNPs was between 97 and 100%. 
Genotyping in the New Zealand cohort was carried out using polymerase chain reaction as 
previously described9. 
Statistical analysis: Hardy-Weinberg equilibrium was tested on a contingency table of observed 
verses predicted phenotype frequencies using a modified Markov-chain random-walk algorithm. To 
test our hypotheses we investigated the association of genotyped SNPs and aortic diameter using 
linear regression adjusting for other risk factors for AAA (age, smoking, CHD, dyslipidemia, 
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hypertension, diabetes, waist to hip ratio). Each of the bi-allelic SNPs was coded into three 
genotype classes and analysed under codominant models (0=major allele homozygote, 
1=heterozygote, 2=minor allele homozygote). Any significant codominant models were explored 
further (dominant and recessive models) to determine the best fitting model using Akaiki 
information criteria. Haplotype frequencies were estimated from unphased genotype data using an 
expectation maximisation algorithm under the assumption of Hardy-Weinberg equilibrium. 
Haplotypes were associated with aortic diameter using a generalized linear recessive model based 
on the initial genotyping results. Computations were undertaken using SimHap v1.0.2 
(http://www.genepi.org.au/simhap.html) and SSPS 14.0 (SPSS Inc., Chicago, IL., USA). Genotypes 
associated with aortic diameter within the HIMS at a Bonferroni corrected p value of <0.0007 
(based on the 74 SNPs assessed) were examined in a second independent cohort.  
 
Results 
Association of genotypes with aortic diameter in the HIMS subjects 
Genotyping was carried out in 1711 HIMS subjects of whom 640 (37%) had an AAA (Table 1). 68 
of the 74 (92%) SNPs passed quality assessments, were in Hardy Weinberg equilibrium in controls 
and therefore were assessed for association with aortic diameter. One SNP in CYP19A1 (CYP19A1 
g.49412370C>T; SNP ID rs1961177) was independently associated with aortic diameter in HIMS 
subjects (Supplemental Table). Median aortic diameters were 24.2 (inter-quartile range 21.1-31.3), 
24.5 (inter-quartile range 21.1-32.7) and 30.6mm (21.9-40.0) for men with CC (n=1317), TC 
(n=329) and TT (n=32) genotypes. CYP19A1 g.49412370C>T (SNP ID rs1961177) was 
independently associated with aortic diameter under a recessive model (coefficient 5.058, standard 
error 1.394, p=0.0003), including Bonferroni correction for multiple testing.  
Haplotype analysis in the HIMS subjects 
A total of 14 linkage dysequilibrium blocks were identified within the CYP19A1 gene using 
HapMap Phase II data (Fig. 1). We assessed the association of haplotype combination from these 
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different blocks with aortic diameter in HIMS subjects. Four haplotypes were demonstrated to be 
significantly associated with aortic diameter, after adjusting for other risk factors and multiple 
testing (Table 2). In particular the relative common haplotype CTT defined by the g.49386747C>G 
(SNP ID rs17523922), g.49394252C>T (SNP ID rs3751591), and g.49412370C>T (SNP ID 
rs1961177) which was present in 10% of men, p=0.0001 (Table 2). 
Genotyping in the New Zealand men 
We further examined g.49412370C>T (SNP ID rs1961177) in an independent cohort of 782 men 
from Otago, 513 (66%) of whom had an AAA. The patients with AAA in the New Zealand sample 
had a mean diameter of just under 6cm, compared to <4cm for the Western Australian men (Tables 
1). CYP19A1 g.49412370C>T (SNP ID rs1961177) was not associated with aortic diameter in the 
New Zealand subjects (coefficient 0.076, standard error 0.284, p=0.788). 
 
Discussion 
To our knowledge this is the first published report examining the association of polymorphisms in 
genes determining circulating sex hormones and aortic diameter. Since male gender is an important 
risk factor for AAA we hypothesised that polymorphisms in four genes important in the production 
and action of sex hormones would be associated with aortic dilatation. One SNP within intron 1 of 
CYP19A1 was strongly associated with aortic diameter within the HIMS cohort which included 
patients with small AAAs. The importance of this genetic locus in aortic dilatation was further 
supported by further analysis which identified a haplotype including this SNP as highly associated 
with aortic diameter in HIMS subjects. This genetic variation within CYP19A1 was not however 
associated with aortic diameter in the New Zealand subjects where patients had much larger AAAs. 
Given the large number of SNPs examined and the lack of replication our findings do not support a 
consistent association between polymorphisms in these genes and aortic diameter in men. Our 
findings do not however rule out a role of the one SNP highlighted in this study in early stage AAA 
formation where different mechanisms may be involved compared to later stage aneurysm 
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progression. Also our study did not examine all genes involved sex hormone production and 
functions such as that encoding estrogen receptor 1. The assessment of the SNP in CYP19A1 in 
another population screened for AAA in which aortic diameter and risk factors have been carefully 
assessed would be worthwhile when such a group becomes available. 
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Legend to the figures 
 
Figure 1: Schematic diagram of linkage disequilibrium blocks within CYP19A1 gene. Black 
triangles represent linkage disequilibrium (LD) blocks; deep red represents strong LD; red to white 
represents moderate to no LD among the single nucleotide polymorphisms. 
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Table 1: Comparison of subjects with and without AAA undergoing genotyping. 
Subjects HIMS New Zealand 
Characteristic AAA No AAA P value AAA No AAA P value 
Number 640 1071  513 269  
Aortic 
diameter (mm) 
36.1±6.7 22.2±3.0 <0.001 59.5±16.8 20.4±0.2 <0.001 
Age (years) 73.3±4.3 73.2±4.3 0.68 72.3±8.0 67.9±6.5 <0.001 
Hypertension 345 (54%) 444 (41%) <0.001 265 (52%) 67 (25%) <0.001 
Diabetes 
mellitus 
67 (10%) 80 (8%) 0.05 40 (8%) 8 (3%) 0.01 
Dyslipidemia 285 (45%) 375 (35%) <0.001 198 (39%) 71 (26%) 0.001 
Ever smoker 551 (86%) 672 (66%) <0.001 444 (87%) 140 (52%) <0.001 
CHD 257 (40%) 228 (21%) <0.001 205 (40%) 0 (0%) <0.001 
Nominal variables are presented as numbers and compared with chi squared. Continuous variables are presented as mean ± standard deviation and 
compared with Mann Whitney U test. CHD= Coronary heart disease. 
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Table 2: The association of CYP19A1 haplotypes with aortic diameter. 
 
SNP ID 
LD 
Block 
Haplotype Frequency Copy Coefficient SE P 
Mean 
aortic 
diameter 
rs12439137 3 
AAT 0.0547 
0 
- - - 27.0 
rs700518 4 1 
rs727479 5 2 7.7420 2.2060 0.0005 34.7 
rs700518 4 
ATT 0.0522 
0 
- - - 27.0 
rs727479 5 1 
rs10459592 6 2 7.1140 2.1210 0.0008 34.1 
rs17703883 4 
TTT 0.0905 
0 
- - - 27.0 
rs727479 5 1 
rs10459592 6 2 5.6600 1.6350 0.0006 32.7 
rs727479 5 
TTG 0.0527 
0 
- - - 27.0 
rs10459592 6 1 
rs767199 7 2 7.1140 2.1210 0.0008 34.1 
rs7172156 8 
GGG 0.0444 
0 
- - - 27.0 
rs3889391 9 1 
rs7181886 10 2 5.8540 2.2110 0.0082 32.9 
rs7172156 8 
GGT 0.0844 
0 
- - - 27.0 
rs3889391 9 1 
rs2470157 10 2 4.3070 1.8120 0.0176 31.3 
rs12050772 8 
TGG 0.0455 
0 
- - - 27.0 
rs3889391 9 1 
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rs7181886 10 2 5.8540 2.2110 0.0082 32.9 
rs3889391 9 
GGC 0.0455 
0 
- - - 27.0 
rs7181886 10 1 
rs17523880 11 2 5.8540 2.2110 0.0082 32.9 
rs7181886 10 
GCC 0.0460 
0 
- - - 27.0 
rs17523880 11 1 
rs17523922 12 2 4.6400 2.1250 0.0291 31.6 
rs2470152 11 
CCC 0.0967 
0 
- - - 27.0 
rs17523922 12 1 
rs3751591 13 2 6.2440 1.7150 0.0003 33.2 
rs17523922 12 
CCT 0.1052 
0 
- - - 27.0 
rs3751591 13 1 
rs2445762 14 2 4.7700 1.7200 0.0056 31.8 
rs17523922 12 
CTT 0.1003 
0 
- - - 27.0 
rs3751591 13 1 
rs1961177 14 2 6.5240 1.6720 0.0001 33.5 
Shown are haplotype frequencies, coefficients and p values for the association of presented 
haplotypes with aortic diameter (mm) using a recessive model and adjusting for other risk factors 
outlined in the methods. The estimated mean aortic diameters and p values are shown for men with 
0 or 1 copies compared to those with 2 copies of each haplotype. Shown in bold are the p values 
below the pre-specified level for significance, taking into account multiple testing. SNP= Single 
nucleotide polymorphism; LD= Linkage dysequilibrium. 
 
 
